2024-03-11

1. Summary of the week

Between March 1st and 8th, 2024, the biotech industry saw a total of 8 agreements for licensing and collaboration. In the Chinese market, HaiheBiopharma and Taiho Pharmaceutical secured the exclusive out-licensing deal in Japan, Asia (excluding China), and Oceania, featuring Gumarontinib (SCC244), an oral MET inhibitor targeting Non-Small Cell Lung Cancer (NSLC). Meanwhile, globally, 7 such agreements were finalized during the same period. Notably, the deal between Merus and Gilead Sciences to develop tri-specific antibodies stood out, boasting an upfront payment of $56 million.

2024年3月1日-8日，全球市场共有8项资产授权和合作交易。中国市场仅有1项，海和药物与日本大鹏药品达成资产授权交易，大鹏药品获得海和药物用于治疗非小细胞肺癌的口服小分子MET抑制剂谷美替尼（SCC244）在日本、亚洲（不包括中国）和大洋洲的开发、生产和商业化的独家权利。全球市场则共有7项资产授权和合作交易。本周最大的交易是Gilead与Merus达成的三特异性抗体研发合作交易，涉及预付款56M美元。

2. Licensing Deals

2a. China section

2b. Global section

3. Top Deals of the year 2024

4. 2019-2023 China Innovative Drug Licensing Transactions

ABOUT YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。